Physician profile
Mark I Soll
NPI 1750367587
$2,369.80
in general payments reported to CMS, 2019-2025
19 companies · $774 in 2025
The $774 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $216 · 2021: $21.78 · 2022: $145 · 2023: $224 · 2024: $141 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.13 |
| Education | $160.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $958.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.16 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $185.90 | 2019-2025 | Dupixent |
| Insmed, INC. | $145.65 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $100.65 | 2019-2025 | Fasenra, Tezspire |
| Resmed Corp | $80.14 | 2019 | |
| Advanced Respiratory, INC | $72.45 | 2019 | |
| Amgen INC. | $71.32 | 2024-2025 | Tezspire |
| Mylan Specialty L.P. | $53.64 | 2019 | |
| Philips North America LLC | $47.89 | 2019-2025 | Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $42.36 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.42 | 2019 | |
| Paratek Pharmaceuticals, INC. | $28.87 | 2025 | Nuzyra |
| Medtronic, INC. | $27.14 | 2023 | Endo Gia Ultra |
| United Therapeutics Corporation | $21.78 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.11 | 2019 | |
| Abbott Laboratories | $15.52 | 2019 | |
| Sandoz INC. | $14.18 | 2019 | |
| Ceribell, INC. | $6.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Soll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.